Arkin Bio News Today

FinSMEs is the financial news site dedicated to covering venture capital, private equity, and merger and acquisition deals in real time!

Taking the opposite approach of targeted protein degradation, biotech company Entact Bio is developing medicines that stabilize proteins and even enhances their function. This approach that could apply to cancer and certain rare diseases and Entact's $81 million in Series A financing enables it to work on multiple programs in parallel.

Launch fueled by syndicate of blue-chip investors co-led by Qiming Venture Partners USA and venBio PartnersCompany’s proprietary end-to-end Encompass™ platform designs enhancement-targeting chimeric (ENTAC™) moleculesFounding team comprised of world-class scientific leadersWATERTOWN, Mass.--(BUSINESS WIRE)--Entact B...

- Phosphorylation-inducing chimeric small molecules (PHICS) are a new class of bifunctional medicines that direct and repair aberrant and dysfunctional proteins- PHICS enable precise phosphorylation, an important post-translational modification that controls protein function, including activation, stabilization, tra...

FinSMEs is the financial news site dedicated to covering venture capital, private equity, and merger and acquisition deals in real time!

Photys Therapeutics has debuted with a $75 million Series A funding round. The startup focuses on phosphorylation-inducing chimeric small molecules (PHICS) — a new class of bifunctional medicines that can direct and repair protein phosphorylation.

Israel Biotech Fund (IBF), founded by Dr. David Sidransky, Dr. Yuval Cabilly and Ido Zairi, announced the closing of its second fund with a total of $112 million. The fund will focus on the investment and formation of Israeli biotech and pharma companies developing drugs at different stages of development and for various indications. Amongst the main limited partners of fund II are Harel Insurance, BMS, an international pharmaceutical company, and the CBG fund. The second fund will continue its...